Drug Trial Radar · NCT00448864
Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair/Replacement
Last checked: Nov 20, 2026Latest source record: Jun 25, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
75
Actual
Start
May 1, 2007
Primary completion
Jul 1, 2008
Study completion Aug 1, 2008
Sponsor
- Lead sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
- Sponsor type
- Industry
- First posted
- Mar 19, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study was to assess the efficacy and safety of 2 dose levels of ecallantide versus placebo in reducing blood loss following cardiopulmonary bypass (CPB), as measured by chest tube drainage during the first 12 hours postoperatively or until the chest tube was removed, whichever came first, in patients undergoing primary coronary artery bypass grafting (CABG), single valve repair, or single valve replacement. The secondary objective was to compare the efficacy of all ecallantide-treated participants (pooled high and low-doses) to placebo and to compare the high-dose to the low-dose ecallantide group. Other secondary objectives were to evaluate pharmacokinetics and antibody formation.
Conditions
- Blood Loss, Surgical
Interventions
EcallantideDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative Chest Tube Drainage During the First 12 Hours PostoperativelyTime frame: Up to 12 hours post admission to intensive care unit (ICU)
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
St. Vincent's Hospital
Birmingham, Alabama
Mayo Clinic Hospital
Phoenix, Arizona
University of Colorado
Aurora, Colorado
Massachusetts General Hospital
Boston, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts
Caritas St. Elizabeth's Medical Center
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Mayo Clinic
Rochester, Minnesota
SUNY Upstate Medical University
Syracuse, New York
Duke University Medical Center
Durham, North Carolina
Gaston Memorial Hospital
Gastonia, North Carolina
Cleveland Clinic
Cleveland, Ohio
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
The Methodist Hospital
Houston, Texas
Texas Heart Institute
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.